Aura Biosciences (AURA) Common Equity (2020 - 2026)

Aura Biosciences' Common Equity history runs 7 years deep, the most recent figure standing at $107.2 million for Q1 2026.

• Quarterly Common Equity fell 16.19% year-over-year to $107.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.2 million (down 16.19% YoY) and the FY2025 annual result came in at $136.9 million, down 9.91% from the prior year.
• Common Equity was $107.2 million for Q1 2026 at Aura Biosciences, down from $136.9 million in the prior quarter.
• Across five years, Common Equity topped out at $225.8 million in Q4 2023 and bottomed at $107.2 million in Q1 2026.
• A 5-year average of $160.9 million and a median of $156.7 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 223.55% — and 2025, when it sank 38.71%.
• Aura Biosciences' Common Equity stood at $195.6 million in 2022, then gained by 15.47% to $225.8 million in 2023, then slumped by 32.71% to $152.0 million in 2024, then decreased by 9.91% to $136.9 million in 2025, then declined by 21.67% to $107.2 million in 2026.
• Business Quant data shows AURA's Common Equity at $107.2 million in Q1 2026, $136.9 million in Q4 2025, and $156.7 million in Q3 2025.